Transgene has completed patient randomization in the Phase 2 portion of its clinical trial evaluating TG4050, an individualized cancer vaccine, as adjuvant treatment for head and neck cancer. The milestone moves the study forward to assessing TG4050’s safety and efficacy in preventing or delaying recurrence following standard treatment. Find out more details in 2 news articles below.